MiR-411 is up-regulated in FSHD myoblasts and suppresses myogenic factors

Orphanet Journal of Rare Diseases

Volumn 8, Issue 1, 2013, Pages

  Harafuji, Naoe ^a   Schneiderat, Peter ^b   Walter, Maggie C ^b   Chen, Yi Wen ^a,c,d  

^a CHILDREN S RESEARCH INSTITUTE   (United States)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c GEORGE WASHINGTON UNIVERSITY   (United States)

^d CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

Author keywords

FSHD; microRNA; miR 411; Myod; myogenin; YAF2; YY1

Indexed keywords

CELL MARKER; MESSENGER RNA; MICRORNA; MICRORNA 411; MYOD PROTEIN; MYOGENIC FACTOR; MYOGENIN; MYOSIN HEAVY CHAIN 1; UNCLASSIFIED DRUG; YY1 ASSOCIATED FACTOR 2 PROTEIN;

ARTICLE; CELL IMMORTALIZATION; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOPLASM; FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; GENE OVEREXPRESSION; GENE TARGETING; GENETIC TRANSCRIPTION; GENOME; GENOMICS; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MICROARRAY ANALYSIS; MUSCLE DEVELOPMENT; MYOBLAST; PROTEIN FOLDING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; UPREGULATION; VALIDATION PROCESS;

CELL LINE, TRANSFORMED; CHROMOSOMES, HUMAN, PAIR 4; GENE EXPRESSION PROFILING; HUMANS; IN SITU HYBRIDIZATION; MICRORNAS; MUSCLE PROTEINS; MUSCULAR DYSTROPHY, FACIOSCAPULOHUMERAL; MYOBLASTS; MYOD PROTEIN; MYOGENIN; REPRESSOR PROTEINS; UP-REGULATION;

EID: 84875851441     PISSN: None     EISSN: 17501172     Source Type: Journal    
DOI: 10.1186/1750-1172-8-55     Document Type: Article

References (96)

1. Facioscapulohumeral muscular dystrophy in the Dutch population. Padberg GW, Frants RR, Brouwer OF, Wijmenga C, Bakker E, Sandkuijl LA, Muscle Nerve 1995 2 81 S84 23573591
2. High proportion of new mutations and possible anticipation in Brazilian facioscapulohumeral muscular dystrophy families. Zatz M, Marie SK, Passos-Bueno MR, Vainzof M, Campiotto S, Cerqueira A, Wijmenga C, Padberg G, Frants R, Am J Hum Genet 1995 56 99 105 7825608
3. Estimation of age dependent penetrance in facioscapulohumeral muscular dystrophy by minimising ascertainment bias. Lunt PW, Compston DA, Harper PS, J Med Genet 1989 26 755 760 10.1136/jmg.26.12.755 2614794 (Pubitemid 20008538)
4. Facioscapulohumeral dystrophy: a distinct regional myopathy with a novel molecular pathogenesis. FSH Consortium. Tawil R, Figlewicz DA, Griggs RC, Weiffenbach B, Ann Neurol 1998 43 279 282 10.1002/ana.410430303 9506542 (Pubitemid 28113588)
5. Diagnostic criteria for facioscapulohumeral muscular dystrophy. Padberg GW, Lunt PW, Koch M, Fardeau M, Neuromuscul Disord 1991 1 231 234 10.1016/0960-8966(91)90094-9 1822799
6. Chromosome 4q DNA rearrangements associated with facioscapulohumeral muscular dystrophy. Wijmenga C, Hewitt JE, Sandkuijl LA, Clark LN, Wright TJ, Dauwerse HG, Gruter AM, Hofker MH, Moerer P, Williamson R, Nat Genet 1992 2 26 30 10.1038/ng0992-26 1363881
7. Padberg GW, Facioscapulohumeral disease University of Leiden: Doctral 1982
8. Facioscapulohumeral Muscular Dystrophy: a Clinician's Experience. Padberg GW, Facioscapulohumeral muscular dystrophy Clinical Medicine and Molecular Cell Biology, Garland Science/BIOS Scientific Publishers, Upadhyaya D, Cooper DN, 2004 41 54
9. Inflammatory response in facioscapulohumeral muscular dystrophy (FSHD): immunocytochemical and genetic analyses. Arahata K, Ishihara T, Fukunaga H, Orimo S, Lee JH, Goto K, Nonaka I, Muscle Nerve 1995 2 56 S66 23573588
10. Facioscapulohumeral muscular dystrophy. Padberg G, Adams C, Neurogenetics Oxford, UK: Oxford University Press, Pulst S-M, 2000 105 116
11. On the significance of retinal vascular disease and hearing loss in facioscapulohumeral muscular dystrophy. Padberg GW, Brouwer OF, de Keizer RJ, Dijkman G, Wijmenga C, Grote JJ, Frants RR, Muscle Nerve 1995 2 73 S80 23573590
12. Monosomy of distal 4q does not cause facioscapulohumeral muscular dystrophy. Tupler R, Berardinelli A, Barbierato L, Frants R, Hewitt JE, Lanzi G, Maraschio P, Tiepolo L, J Med Genet 1996 33 366 370 10.1136/jmg.33.5.366 8733044 (Pubitemid 26147866)
13. Facioscapulohumeral muscular dystrophy. van der Maarel SM, Frants RR, Padberg GW, Biochim Biophys Acta 2007 1772 186 194 10.1016/j.bbadis.2006.05.009 16837171 (Pubitemid 46123910)
14. FSHD associated DNA rearrangements are due to deletions of integral copies of a 3.2 kb tandemly repeated unit. van Deutekom JC, Wijmenga C, van Tienhoven EA, Gruter AM, Hewitt JE, Padberg GW, van Ommen GJ, Hofker MH, Frants RR, Hum Mol Genet 1993 2 2037 2042 10.1093/hmg/2.12.2037 8111371 (Pubitemid 24003395)
15. High resolution fluorescence in situ hybridization to linearly extended DNA visually maps a tandem repeat associated with facioscapulohumeral muscular dystrophy immediately adjacent to the telomere of 4q. Bengtsson U, Altherr MR, Wasmuth JJ, Winokur ST, Hum Mol Genet 1994 3 1801 1805 10.1093/hmg/3.10.1801 7849703
16. Analysis of the tandem repeat locus D4Z4 associated with facioscapulohumeral muscular dystrophy. Hewitt JE, Lyle R, Clark LN, Valleley EM, Wright TJ, Wijmenga C, van Deutekom JC, Francis F, Sharpe PT, Hofker M, Hum Mol Genet 1994 3 1287 1295 10.1093/hmg/3.8.1287 7987304 (Pubitemid 24255461)
17. DUX4, a candidate gene of facioscapulohumeral muscular dystrophy, encodes a transcriptional activator of PITX1. Dixit M, Ansseau E, Tassin A, Winokur S, Shi R, Qian H, Sauvage S, Matteotti C, van Acker AM, Leo O, Proc Natl Acad Sci U S A 2007 104 18157 18162 10.1073/pnas.0708659104 17984056 (Pubitemid 350210837)
18. Facioscapulohumeral dystrophy: incomplete suppression of a retrotransposed gene. Snider L, Geng LN, Lemmers RJ, Kyba M, Ware CB, Nelson AM, Tawil R, Filippova GN, van der Maarel SM, Tapscott SJ, Miller DG, PLoS Genet 2010 6 1001181 10.1371/journal.pgen.1001181 21060811
19. RNA transcripts, miRNA-sized fragments and proteins produced from D4Z4 units: new candidates for the pathophysiology of facioscapulohumeral dystrophy. Snider L, Asawachaicharn A, Tyler AE, Geng LN, Petek LM, Maves L, Miller DG, Lemmers RJ, Winokur ST, Tawil R, Hum Mol Genet 2009 18 2414 2430 10.1093/hmg/ddp180 19359275
20. An isogenetic myoblast expression screen identifies DUX4-mediated FSHD-associated molecular pathologies. Bosnakovski D, Xu Z, Gang EJ, Galindo CL, Liu M, Simsek T, Garner HR, Agha-Mohammadi S, Tassin A, Coppee F, EMBO J 2008 27 2766 2779 10.1038/emboj.2008.201 18833193
21. The DUX4 gene at the FSHD1A locus encodes a pro-apoptotic protein. Kowaljow V, Marcowycz A, Ansseau E, Conde CB, Sauvage S, Matteotti C, Arias C, Corona ED, Nunez NG, Leo O, Neuromuscul Disord 2007 17 611 623 10.1016/j.nmd.2007.04.002 17588759 (Pubitemid 47030917)
22. Testing the effects of FSHD candidate gene expression in vertebrate muscle development. Wuebbles RD, Long SW, Hanel ML, Jones PL, Int J Clin Exp Pathol 2010 3 386 400 20490329
23. DUX4, a candidate gene for facioscapulohumeral muscular dystrophy, causes p53-dependent myopathy in vivo. Wallace LM, Garwick SE, Mei W, Belayew A, Coppee F, Ladner KJ, Guttridge D, Yang J, Harper SQ, Ann Neurol 2010
24. The FSHD atrophic myotube phenotype is caused by DUX4 expression. Vanderplanck C, Ansseau E, Charron S, Stricwant N, Tassin A, Laoudj-Chenivesse D, Wilton SD, Coppee F, Belayew A, PLoS One 2011 6 26820 10.1371/journal.pone. 0026820 22053214
25. Conditional over-expression of PITX1 causes skeletal muscle dystrophy in mice. Pandey SN, Cabotage J, Shi R, Dixit M, Sutherland M, Liu J, Muger S, Harper SQ, Nagaraju K, Chen YW, Biol Open 2012 1 629 639 10.1242/bio.20121305 23125914
26. Hypomethylation of D4Z4 in 4q-linked and non-4q-linked facioscapulohumeral muscular dystrophy. van Overveld PG, Lemmers RJ, Sandkuijl LA, Enthoven L, Winokur ST, Bakels F, Padberg GW, van Ommen GJ, Frants RR, van der Maarel SM, Nat Genet 2003 35 315 317 10.1038/ng1262 14634647 (Pubitemid 37486913)
27. A Unifying Genetic Model for Facioscapulohumeral Muscular Dystrophy. Lemmers RJ, van der Vliet PJ, Klooster R, Sacconi S, Camano P, Dauwerse JG, Snider L, Straasheijm KR, Jan Van Ommen G, Padberg GW, Science 2010 329 1650 1653 10.1126/science.1189044 20724583
28. Gene expression during normal and FSHD myogenesis. Tsumagari K, Chang SC, Lacey M, Baribault C, Chittur SV, Sowden J, Tawil R, Crawford GE, Ehrlich M, BMC Med Genomics 2011 4 67 10.1186/1755-8794-4-67 21951698
29. Expression profiling of FSHD muscle supports a defect in specific stages of myogenic differentiation. Winokur ST, Chen YW, Masny PS, Martin JH, Ehmsen JT, Tapscott SJ, van der Maarel SM, Hayashi Y, Flanigan KM, Hum Mol Genet 2003 12 2895 2907 10.1093/hmg/ddg327 14519683 (Pubitemid 37442018)
30. Parallel protein and transcript profiles of FSHD patient muscles correlate to the D4Z4 arrangement and reveal a common impairment of slow to fast fibre differentiation and a general deregulation of MyoD-dependent genes. Celegato B, Capitanio D, Pescatori M, Romualdi C, Pacchioni B, Cagnin S, Vigano A, Colantoni L, Begum S, Ricci E, Proteomics 2006 6 5303 5321 10.1002/pmic.200600056 17013991 (Pubitemid 44547168)
31. Expression profiling of FSHD-1 and FSHD-2 cells during myogenic differentiation evidences common and distinctive gene dysregulation patterns. Cheli S, Francois S, Bodega B, Ferrari F, Tenedini E, Roncaglia E, Ferrari S, Ginelli E, Meneveri R, PLoS One 2011 6 20966 10.1371/journal.pone.0020966 21695143
32. Facioscapulohumeral muscular dystrophy (FSHD) myoblasts demonstrate increased susceptibility to oxidative stress. Winokur ST, Barrett K, Martin JH, Forrester JR, Simon M, Tawil R, Chung SA, Masny PS, Figlewicz DA, Neuromuscul Disord 2003 13 322 333 10.1016/S0960-8966(02)00284-5 12868502 (Pubitemid 36966161)
33. Myoblasts from affected and non-affected FSHD muscles exhibit morphological differentiation defects. Barro M, Carnac G, Flavier S, Mercier J, Vassetzky Y, Laoudj-Chenivesse D, J Cell Mol Med 2010 14 275 289 10.1111/j.1582-4934.2008.00368.x 18505476
34. Facioscapulohumeral muscular dystrophy. Tawil R, Neurotherapeutics 2008 5 601 606 10.1016/j.nurt.2008.07.005 19019312
35. MicroRNAs in development and disease. Sayed D, Abdellatif M, Physiol Rev 2011 91 827 887 10.1152/physrev.00006.2010 21742789
36. Many roads to maturity: microRNA biogenesis pathways and their regulation. Winter J, Jung S, Keller S, Gregory RI, Diederichs S, Nat Cell Biol 2009 11 228 234 10.1038/ncb0309-228 19255566
37. The nuclear RNase III Drosha initiates microRNA processing. Lee Y, Ahn C, Han J, Choi H, Kim J, Yim J, Lee J, Provost P, Radmark O, Kim S, Kim VN, Nature 2003 425 415 419 10.1038/nature01957 14508493 (Pubitemid 37187272)
38. Nuclear export of microRNA precursors. Lund E, Guttinger S, Calado A, Dahlberg JE, Kutay U, Science 2004 303 95 98 10.1126/science.1090599 14631048 (Pubitemid 38055779)
39. Evidence that siRNAs function as guides, not primers, in the Drosophila and human RNAi pathways. Schwarz DS, Hutvagner G, Haley B, Zamore PD, Mol Cell 2002 10 537 548 10.1016/S1097-2765(02)00651-2 12408822 (Pubitemid 35284172)
40. MicroRNAs in skeletal muscle: their role and regulation in development, disease and function. Guller I, Russell AP, J Physiol 588 4075 4087
41. MicroRNAs: genomics, biogenesis, mechanism, and function. Bartel DP, Cell 2004 116 281 297 10.1016/S0092-8674(04)00045-5 14744438 (Pubitemid 38167318)
42. Small non-coding RNAs in animal development. Stefani G, Slack FJ, Nat Rev Mol Cell Biol 2008 9 219 230 10.1038/nrm2347 18270516 (Pubitemid 351301826)
43. Control of translation and mRNA degradation by miRNAs and siRNAs. Valencia-Sanchez MA, Liu J, Hannon GJ, Parker R, Genes Dev 2006 20 515 524 10.1101/gad.1399806 16510870 (Pubitemid 43345317)
44. Microrna-221 and microrna-222 modulate differentiation and maturation of skeletal muscle cells. Cardinali B, Castellani L, Fasanaro P, Basso A, Alema S, Martelli F, Falcone G, PLoS One 2009 4 7607 10.1371/journal.pone.0007607 19859555
45. Myogenic factors that regulate expression of muscle-specific microRNAs. Rao PK, Kumar RM, Farkhondeh M, Baskerville S, Lodish HF, Proc Natl Acad Sci U S A 2006 103 8721 8726 10.1073/pnas.0602831103 16731620 (Pubitemid 43878086)
46. The role of microRNA-1 and microRNA-133 in skeletal muscle proliferation and differentiation. Chen JF, Mandel EM, Thomson JM, Wu Q, Callis TE, Hammond SM, Conlon FL, Wang DZ, Nat Genet 2006 38 228 233 10.1038/ng1725 16380711 (Pubitemid 43177239)
47. microRNA-1 and microRNA-206 regulate skeletal muscle satellite cell proliferation and differentiation by repressing Pax7. Chen JF, Tao Y, Li J, Deng Z, Yan Z, Xiao X, Wang DZ, J Cell Biol 2010 190 867 879 10.1083/jcb.200911036 20819939
48. The microRNA miR-181 targets the homeobox protein Hox-A11 during mammalian myoblast differentiation. Naguibneva I, Ameyar-Zazoua M, Polesskaya A, Ait-Si-Ali S, Groisman R, Souidi M, Cuvellier S, Harel-Bellan A, Nat Cell Biol 2006 8 278 284 10.1038/ncb1373 16489342 (Pubitemid 43336070)
49. MicroRNA-214 promotes myogenic differentiation by facilitating exit from mitosis via down-regulation of proto-oncogene N-ras. Liu J, Luo XJ, Xiong AW, Zhang ZD, Yue S, Zhu MS, Cheng SY, J Biol Chem 285 26599 26607
50. Transforming growth factor-beta-regulated miR-24 promotes skeletal muscle differentiation. Sun Q, Zhang Y, Yang G, Chen X, Cao G, Wang J, Sun Y, Zhang P, Fan M, Shao N, Yang X, Nucleic Acids Res 2008 36 2690 2699 10.1093/nar/gkn032 18353861 (Pubitemid 351659582)
51. Zebrafish miR-214 modulates Hedgehog signaling to specify muscle cell fate. Flynt AS, Li N, Thatcher EJ, Solnica-Krezel L, Patton JG, Nat Genet 2007 39 259 263 10.1038/ng1953 17220889 (Pubitemid 46184359)
52. MicroRNA-206 is overexpressed in the diaphragm but not the hindlimb muscle of mdx mouse. McCarthy JJ, Esser KA, Andrade FH, Am J Physiol Cell Physiol 2007 293 451 457 10.1152/ajpcell.00077.2007 17459947 (Pubitemid 47105025)
53. Overexpression of microRNA-206 in the skeletal muscle from myotonic dystrophy type 1 patients. Gambardella S, Rinaldi F, Lepore SM, Viola A, Loro E, Angelini C, Vergani L, Novelli G, Botta A, J Transl Med 8 48
54. MicroRNAs involved in molecular circuitries relevant for the Duchenne muscular dystrophy pathogenesis are controlled by the dystrophin/nNOS pathway. Cacchiarelli D, Martone J, Girardi E, Cesana M, Incitti T, Morlando M, Nicoletti C, Santini T, Sthandier O, Barberi L, Cell Metab 2010 12 341 351 10.1016/j.cmet.2010.07.008 20727829
55. Distinctive patterns of microRNA expression in primary muscular disorders. Eisenberg I, Eran A, Nishino I, Moggio M, Lamperti C, Amato AA, Lidov HG, Kang PB, North KN, Mitrani-Rosenbaum S, Proc Natl Acad Sci U S A 2007 104 17016 17021 10.1073/pnas.0708115104 17942673 (Pubitemid 350210983)
56. Origin, evolution, and biological role of miRNA cluster in DLK-DIO3 genomic region in placental mammals. Glazov EA, McWilliam S, Barris WC, Dalrymple BP, Mol Biol Evol 2008 25 939 948 10.1093/molbev/msn045 18281269
57. Mef2-mediated transcription of the miR379-410 cluster regulates activity-dependent dendritogenesis by fine-tuning Pumilio2 protein levels. Fiore R, Khudayberdiev S, Christensen M, Siegel G, Flavell SW, Kim TK, Greenberg ME, Schratt G, EMBO J 2009 28 697 710 10.1038/emboj.2009.10 19197241
58. Establishment of clonal myogenic cell lines from severely affected dystrophic muscles-CDK4 maintains the myogenic population. Stadler G, Chen JC, Wagner K, Robin JD, Shay JW, Emerson CP Jr, Wright WE, Skelet Muscle 2011 1 12 10.1186/2044-5040-1-12 21798090
59. A unique library of myogenic cells from facioscapulohumeral muscular dystrophy subjects and unaffected relatives: family, disease and cell function. Homma S, Chen JC, Rahimov F, Beermann ML, Hanger K, Bibat GM, Wagner KR, Kunkel LM, Emerson CP Jr, Miller JB, Eur J Hum Genet 2012 20 404 410 10.1038/ejhg.2011.213 22108603
60. Response of rat muscle to acute resistance exercise defined by transcriptional and translational profiling. Chen YW, Nader GA, Baar KR, Fedele MJ, Hoffman EP, Esser KA, J Physiol 2002 545 27 41 10.1113/jphysiol.2002.021220 12433947 (Pubitemid 35386128)
61. Expression profiling in the muscular dystrophies: identification of novel aspects of molecular pathophysiology. Chen YW, Zhao P, Borup R, Hoffman EP, J Cell Biol 2000 151 1321 1336 10.1083/jcb.151.6.1321 11121445
62. The Problem of Negative Estimates of Variance Components. Thompson WA Jr, Ann Math Statist 1962 33 273 289 10.1214/aoms/1177704731
63. Quantitative real-time PCR protocol for analysis of nuclear receptor signaling pathways. Bookout AL, Mangelsdorf DJ, Nucl Recept Signal 2003 1 012 16604184
64. Guide to Performing Relative Quantitation of Gene Expression Using Real-Time Quantitative PCR Applied Biosystems
65. Molecular responses of human muscle to eccentric exercise. Chen YW, Hubal MJ, Hoffman EP, Thompson PD, Clarkson PM, J Appl Physiol 2003 95 2485 2494 12937035 (Pubitemid 37444994)
66. The isolated muscle fibre as a model of disuse atrophy: characterization using PhAct, a method to quantify f-actin. Duddy WJ, Cohen T, Duguez S, Partridge TA, Exp Cell Res 2011 317 1979 1993 10.1016/j.yexcr.2011.05.013 21635888
67. Wilkinson DG, in situ hybridization: a practical approach Oxford University Press 1992
68. NIH Image to ImageJ: 25 years of image analysis. Schneider CA, Rasband WS, Eliceiri KW, Nat Methods 2012 9 671 675 10.1038/nmeth.2089 22930834
69. FRG2, an FSHD candidate gene, is transcriptionally upregulated in differentiating primary myoblast cultures of FSHD patients. Rijkers T, Deidda G, van Koningsbruggen S, van Geel M, Lemmers RJ, van Deutekom JC, Figlewicz D, Hewitt JE, Padberg GW, Frants RR, van der Maarel SM, J Med Genet 2004 41 826 836 10.1136/jmg.2004.019364 15520407 (Pubitemid 39524309)
70. Yeast two-hybrid cloning of a novel zinc finger protein that interacts with the multifunctional transcription factor YY1. Kalenik JL, Chen D, Bradley ME, Chen SJ, Lee TC, Nucleic Acids Res 1997 25 843 849 10.1093/nar/25.4.843 9016636 (Pubitemid 27299842)
71. Functional antagonism between YY1 and the serum response factor. Gualberto A, LePage D, Pons G, Mader SL, Park K, Atchison ML, Walsh K, Mol Cell Biol 1992 12 4209 4214 1508214
72. Activation of skeletal alpha-actin gene transcription: the cooperative formation of serum response factor-binding complexes over positive cis-acting promoter serum response elements displaces a negative-acting nuclear factor enriched in replicating myoblasts and nonmyogenic cells. Lee TC, Chow KL, Fang P, Schwartz RJ, Mol Cell Biol 1991 11 5090 5100 1922033 (Pubitemid 21895270)
73. The mouse YAF2 gene generates two distinct transcripts and is expressed in pre-and postimplantation embryos. Kaneko T, Miyagishima H, Hasegawa T, Mizutani-Koseki Y, Isono K, Koseki H, Gene 2003 315 183 192 14557078 (Pubitemid 37214910)
74. YEAF1/RYBP and YAF-2 are functionally distinct members of a cofactor family for the YY1 and E4TF1/hGABP transcription factors. Sawa C, Yoshikawa T, Matsuda-Suzuki F, Delehouzee S, Goto M, Watanabe H, Sawada J, Kataoka K, Handa H, J Biol Chem 2002 277 22484 22490 10.1074/jbc.M203060200 11953439 (Pubitemid 34967221)
75. Polycomb silencers control cell fate, development and cancer. Sparmann A, van Lohuizen M, Nat Rev Cancer 2006 6 846 856 10.1038/nrc1991 17060944 (Pubitemid 44629896)
76. Inappropriate gene activation in FSHD: a repressor complex binds a chromosomal repeat deleted in dystrophic muscle. Gabellini D, Green MR, Tupler R, Cell 2002 110 339 348 10.1016/S0092-8674(02)00826-7 12176321
77. GABP, HCF-1 and YY1 are involved in Rb gene expression during myogenesis. Delehouzee S, Yoshikawa T, Sawa C, Sawada J, Ito T, Omori M, Wada T, Yamaguchi Y, Kabe Y, Handa H, Genes Cells 2005 10 717 731 10.1111/j.1365-2443.2005.00873.x 15966902 (Pubitemid 40932351)
78. NF-kappaB-YY1-miR-29 regulatory circuitry in skeletal myogenesis and rhabdomyosarcoma. Wang H, Garzon R, Sun H, Ladner KJ, Singh R, Dahlman J, Cheng A, Hall BM, Qualman SJ, Chandler DS, Cancer Cell 2008 14 369 381 10.1016/j.ccr.2008.10.006 18977326
79. MyoD distal regulatory region contains an SRF binding CArG element required for MyoD expression in skeletal myoblasts and during muscle regeneration. L'Honore A, Lamb NJ, Vandromme M, Turowski P, Carnac G, Fernandez A, Mol Biol Cell 2003 14 2151 2162 10.1091/mbc.E02-07-0451 12802082 (Pubitemid 36583560)
80. The serum response element. Treisman R, Trends Biochem Sci 1992 17 423 426 10.1016/0968-0004(92)90013-Y 1455511
81. Serum response factor p67SRF is expressed and required during myogenic differentiation of both mouse C2 and rat L6 muscle cell lines. Vandromme M, Gauthier-Rouviere C, Carnac G, Lamb N, Fernandez A, J Cell Biol 1992 118 1489 1500 10.1083/jcb.118.6.1489 1522119
82. Expression and activity of serum response factor is required for expression of the muscle-determining factor MyoD in both dividing and differentiating mouse C2C12 myoblasts. Gauthier-Rouviere C, Vandromme M, Tuil D, Lautredou N, Morris M, Soulez M, Kahn A, Fernandez A, Lamb N, Mol Biol Cell 1996 7 719 729 8744946 (Pubitemid 26139270)
83. Growth and differentiation of C2 myogenic cells are dependent on serum response factor. Soulez M, Rouviere CG, Chafey P, Hentzen D, Vandromme M, Lautredou N, Lamb N, Kahn A, Tuil D, Mol Cell Biol 1996 16 6065 6074 8887636 (Pubitemid 26360966)
84. NF-kappaB regulation of YY1 inhibits skeletal myogenesis through transcriptional silencing of myofibrillar genes. Wang H, Hertlein E, Bakkar N, Sun H, Acharyya S, Wang J, Carathers M, Davuluri R, Guttridge DC, Mol Cell Biol 2007 27 4374 4387 10.1128/MCB.02020-06 17438126 (Pubitemid 46906562)
85. DUX4 activates germline genes, retroelements, and immune mediators: implications for facioscapulohumeral dystrophy. Geng LN, Yao Z, Snider L, Fong AP, Cech JN, Young JM, van der Maarel SM, Ruzzo WL, Gentleman RC, Tawil R, Tapscott SJ, Dev Cell 2012 22 38 51 10.1016/j.devcel.2011.11.013 22209328
86. Normal growth and regenerating ability of myoblasts from unaffected muscles of facioscapulohumeral muscular dystrophy patients. Vilquin JT, Marolleau JP, Sacconi S, Garcin I, Lacassagne MN, Robert I, Ternaux B, Bouazza B, Larghero J, Desnuelle C, Gene Ther 2005 12 1651 1662 10.1038/sj.gt.3302565 15973444 (Pubitemid 41670355)
87. Isolation and characterization of mesoangioblasts from facioscapulohumeral muscular dystrophy muscle biopsies. Morosetti R, Mirabella M, Gliubizzi C, Broccolini A, Sancricca C, Pescatori M, Gidaro T, Tasca G, Frusciante R, Tonali PA, Stem Cells 2007 25 3173 3182 10.1634/stemcells.2007- 0465 17761758 (Pubitemid 350294443)
88. Regulating a master regulator: establishing tissue-specific gene expression in skeletal muscle. Aziz A, Liu QC, Dilworth FJ, Epigenetics 2010 5 691 695 10.4161/epi.5.8.13045 20716948
89. MyoD or Myf-5 is required for the formation of skeletal muscle. Rudnicki MA, Schnegelsberg PN, Stead RH, Braun T, Arnold HH, Jaenisch R, Cell 1993 75 1351 1359 10.1016/0092-8674(93)90621-V 8269513 (Pubitemid 24021909)
90. Genome-wide MyoD binding in skeletal muscle cells: a potential for broad cellular reprogramming. Cao Y, Yao Z, Sarkar D, Lawrence M, Sanchez GJ, Parker MH, MacQuarrie KL, Davison J, Morgan MT, Ruzzo WL, Dev Cell 2010 18 662 674 10.1016/j.devcel.2010.02.014 20412780
91. Promoter-specific regulation of MyoD binding and signal transduction cooperate to pattern gene expression. Bergstrom DA, Penn BH, Strand A, Perry RL, Rudnicki MA, Tapscott SJ, Mol Cell 2002 9 587 600 10.1016/S1097-2765(02)00481-1 11931766 (Pubitemid 34273789)
92. MyoD induces retinoblastoma gene expression during myogenic differentiation. Martelli F, Cenciarelli C, Santarelli G, Polikar B, Felsani A, Caruso M, Oncogene 1994 9 3579 3590 7970718 (Pubitemid 24359396)
93. Correlation of terminal cell cycle arrest of skeletal muscle with induction of p21 by MyoD. Halevy O, Novitch BG, Spicer DB, Skapek SX, Rhee J, Hannon GJ, Beach D, Lassar AB, Science 1995 267 1018 1021 10.1126/science. 7863327 7863327
94. Transfection of a DNA locus that mediates the conversion of 10T1/2 fibroblasts to myoblasts. Lassar AB, Paterson BM, Weintraub H, Cell 1986 47 649 656 10.1016/0092-8674(86)90507-6 2430720 (Pubitemid 17011408)
95. Expression of a single transfected cDNA converts fibroblasts to myoblasts. Davis RL, Weintraub H, Lassar AB, Cell 1987 51 987 1000 10.1016/0092-8674(87)90585-X 3690668
96. Generation of isogenic D4Z4 contracted and noncontracted immortal muscle cell clones from a mosaic patient: a cellular model for FSHD. Krom YD, Dumonceaux J, Mamchaoui K, den Hamer B, Mariot V, Negroni E, Geng LN, Martin N, Tawil R, Tapscott SJ, Am J Pathol 2012 181 1387 1401 10.1016/j.ajpath.2012.07. 007 22871573